Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04762641
Recruitment Status : Recruiting
First Posted : February 21, 2021
Last Update Posted : October 6, 2021
Sponsor:
Information provided by (Responsible Party):
ABL Bio, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 15, 2023
Estimated Study Completion Date : June 15, 2023